UK genetics guidelines promise boost in cascade screening
This article was originally published in Clinica
Executive Summary
Genetic testing guidelines published yesterday in the UK may significantly increase the use of so-called “cascade” screening for familial predisposition.
You may also be interested in...
UK Has ‘Much Room For Improvement’ On Genomic Testing Access
UK patient outcomes would improve under clearer, standardized market access or reimbursement pathways for advanced diagnostic tests, such as those used to screen for cancer, trade groups say.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.